Frontiers in Cardiovascular Medicine is a leading open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing research in the field of cardiology and cardiovascular medicine. Since its inception in 2014, the journal has become a vital platform for the dissemination of high-quality research, boasting a commendable Q2 rank in the 2023 category for Cardiology and Cardiovascular Medicine. With a focus on promoting innovative studies and clinical insights, Frontiers in Cardiovascular Medicine facilitates open access to its content, allowing researchers, healthcare professionals, and students from around the globe to engage with the latest findings which are critical for the advancement of cardiovascular health. The journal's significant presence in the academic landscape, as indicated by its Scopus ranking (161/387 and 58th percentile), underscores its importance as a research outlet in this essential field. Located in Lausanne, Switzerland, the journal continues to support the global cardiovascular community by encouraging collaboration and knowledge sharing to address the challenges faced in cardiovascular medicine today.

HYPERTENSION IN PREGNANCY is a leading academic journal dedicated to the critical study of hypertensive disorders during pregnancy, a crucial area of maternal and fetal health. Published by Taylor & Francis Inc, this journal boasts an Open Access policy since 2023, ensuring that research findings are freely accessible to a global audience. With an ISSN of 1064-1955 and E-ISSN of 1525-6065, it offers a platform for high-quality research and review articles since its inception in 1982. The journal holds a Q3 category ranking in both Internal Medicine and Obstetrics and Gynecology, reflecting its reputable standing within the scientific community. As of 2023, it ranks among the top quartile publications in its field, with Scopus ranking it 86/209 in Obstetrics and Gynecology and 83/167 in Internal Medicine. This journal aims to foster dialogue among researchers, clinicians, and policymakers regarding the management and implications of hypertension in pregnancy, promoting advancements in care and research methodologies. Located in Philadelphia, PA, it continues to be an invaluable resource for those invested in improving maternal health outcomes and advancing the field.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

FREE RADICAL BIOLOGY AND MEDICINE, published by Elsevier Science Inc, is a premier journal dedicated to the field of biochemistry and medical physiology. With an ISSN of 0891-5849 and an E-ISSN of 1873-4596, this journal stands out with its impressive ranking in the 2023 category quartiles: Q1 in Biochemistry and Q1 in Physiology (medical). Specifically, it has achieved a remarkable position of 29th out of 438 in Biochemistry and 8th out of 113 in Physiology, placing it firmly in the 93rd percentile of its field, as per Scopus rankings. Since its inception in 1987, the journal has focused on advancing the understanding of free radicals and their role in biological processes, encompassing a wide range of topics from oxidative stress to therapeutic applications. Although it does not currently offer open access, the journal's rigorous peer-review process and impactful research ensure that it remains a valuable resource for researchers and professionals seeking to explore the intricate relationships between free radicals and health. The journal's headquarters are located at STE 800, 230 Park Ave, New York, NY 10169, reflecting its esteemed place within the scientific community and commitment to high-quality research.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

BLOOD PRESSURE is a distinguished journal published by Taylor & Francis Ltd in the field of cardiology and internal medicine, with an ISSN of 0803-7051 and E-ISSN of 1651-1999. Since its inception in 1992, it has become a vital source of research and clinical information, dedicated to advancing our understanding of blood pressure-related health issues. With a notable categorization of Q3 in Cardiology and Cardiovascular Medicine and Q2 in Internal Medicine as of 2023, this journal exemplifies a commitment to evidence-based findings that impact clinical practice and patient care. The journal facilitates a platform for original research, reviews, and case studies, aiming to bridge the gap between researchers and practitioners. Although it does not currently offer open access, BLOOD PRESSURE remains an essential resource for professionals and students alike, striving to enhance health outcomes through dedication to innovative cardiovascular research.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Turkish Journal of Nephrology, published by AVES, serves as a pivotal platform for disseminating significant research in the domains of nephrology, transplantation, and surgery. Since its establishment as an Open Access journal in 2019, it has gained traction for delivering high-quality, peer-reviewed articles that reflect the latest advancements and practices in these critical medical fields. Based in Turkey, this journal has rapidly become an important resource, particularly for researchers and healthcare professionals striving to enhance kidney healthcare strategies. Despite being categorized in the fourth quartile across its main categories for 2023 and having modest rankings within Scopus, its commitment to openness and accessibility fosters a collaborative academic environment that promotes knowledge sharing. We encourage scholars, practitioners, and students to engage with the journal's content to further drive innovation and improve patient outcomes in nephrology and associated disciplines.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.